Monday, November 25, 2019 7:38:35 AM
https://www.researchgate.net/publication/328830731_A_randomized_controlled_double-blind_study_comparing_the_efficacy_and_safety_of_dose-ranging_voclosporin_with_placebo_in_achieving_remission_in_patients_with_active_lupus_nephritis
just to be clear, again, I am not saying that they will fail P3. if the delta of 10% as mentioned in the CC is enough to get a p<0.05 then it is still doable. All I was saying through my posts yesterday that I don't think they can beat P2 numbers , that is all. Few things to consider in this P3 that are different than P2:
1) the race mix is different, no Asian Indian and less White and increase in Hispanic and Black
2) more patients with a longer history of LN but management said it is less than 10% and won't impact the results
3) the change in race could impact the % of patients achieving a CR after 24 weeks. in P2, 100% remained in CR after 24 weeks but this can change now with a different pool of patients ( remember that AURION had 2 patients out of 7 relapse between 24 and 48 weeks , and they were Asian)
my final take on this is that P2 were the best results we could have. P3 will have lower % but I still believe strongly that it will be enough to give us a p<0.05, and this is all we need to get a potential approval from the FDA.
Also, we should never forget the safety issue. this is a wild card and there is no concrete de risk, even though I am more comfortable with the measures they took in this phase
Recent AUPH News
- Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis • Business Wire • 09/24/2024 12:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 08:56:55 PM
- Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference • Business Wire • 09/13/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 08:08:25 PM
- Aurinia Announces Board Restructuring • Business Wire • 09/12/2024 08:05:00 PM
- Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial • Business Wire • 09/05/2024 10:00:00 AM
- Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 08/28/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:06:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 10:07:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:03:38 AM
- Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results • Business Wire • 08/01/2024 10:00:00 AM
- Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 • Business Wire • 07/19/2024 10:00:00 AM
- Aurinia to Participate in Upcoming Investor Healthcare Conferences • Business Wire • 07/02/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:25:28 PM
- Aurinia Announces 2024 Annual General Meeting Results • Business Wire • 06/14/2024 04:16:00 PM
- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 • Business Wire • 06/05/2024 10:00:00 AM
- Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce • Business Wire • 06/04/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/04/2024 09:25:39 PM
- Aurinia Provides Update on Proxy Statement • Business Wire • 06/03/2024 10:30:00 PM
- Aurinia Will Attend 2024 Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:11:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:09:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:07:15 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM